IMRX logo

IMRX
Immuneering Corp

2,971
Mkt Cap
$340.72M
Volume
532,201.00
52W High
$10.08
52W Low
$1.10
PE Ratio
-3.86
IMRX Fundamentals
Price
$5.33
Prev Close
$5.27
Open
$5.32
50D MA
$5.07
Beta
1.42
Avg. Volume
1.12M
EPS (Annual)
-$1.27
P/B
1.58
Rev/Employee
$0.00
$120.59
Loading...
Loading...
News
all
press releases
Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Analysts
Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendat...
MarketBeat·10d ago
News Placeholder
More News
News Placeholder
Immuneering (IMRX) to Release Earnings on Thursday
Immuneering (NASDAQ:IMRX) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 19. (View Earnings Report at...
MarketBeat·21d ago
News Placeholder
Immuneering's (IMRX) "Buy" Rating Reiterated at Needham & Company LLC
Needham & Company LLC reissued a "buy" rating and issued a $11.00 price objective on shares of Immuneering in a research note on Monday...
MarketBeat·24d ago
News Placeholder
Immuneering (NASDAQ:IMRX) Raised to Hold at Wall Street Zen
Wall Street Zen upgraded shares of Immuneering from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·26d ago
News Placeholder
Monashee Investment Management LLC Makes New Investment in Immuneering Corporation $IMRX
Monashee Investment Management LLC acquired a new stake in Immuneering Corporation (NASDAQ:IMRX - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and...
MarketBeat·1mo ago
News Placeholder
Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3
Immuneering (NASDAQ:IMRX) Chief Executive Officer and co-founder Ben Zeskind told attendees at Oppenheimer's 36th Annual Healthcare Life Sciences Conference that the company is focused on improving...
MarketBeat·1mo ago
News Placeholder
Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Brokerages
Immuneering Corporation (NASDAQ:IMRX - Get Free Report) has received an average recommendation of "Moderate Buy" from the seven analysts that are covering the stock, MarketBeat reports. One...
MarketBeat·1mo ago
News Placeholder
Sanofi Invests $18.96 Million in Immuneering Corporation $IMRX
Sanofi bought a new stake in shares of Immuneering Corporation (NASDAQ:IMRX - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The...
MarketBeat·2mo ago
News Placeholder
Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Immuneering Corporation (NASDAQ:IMRX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seven research firms that are currently covering the firm, Marketbeat reports...
MarketBeat·2mo ago
News Placeholder
Immuneering (NASDAQ:IMRX) Insider Purchases $24,990.00 in Stock
Immuneering Corporation (NASDAQ:IMRX - Get Free Report) insider Harold Eugene Brakewood purchased 5,250 shares of the business's stock in a transaction dated Friday, January 16th. The shares were...
MarketBeat·2mo ago
<
1
2
...
>

Latest IMRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.